Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats

Background/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was...

Full description

Bibliographic Details
Main Authors: Dorota Harasiuk, Marcin Baranowski, Piotr Zabielski, Adrian Chabowski, Jan Górski
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2016-06-01
Series:Cellular Physiology and Biochemistry
Subjects:
DAG
Online Access:http://www.karger.com/Article/FullText/445629
id doaj-e9231fca7e744f01a24dc46f8ccf84cd
record_format Article
spelling doaj-e9231fca7e744f01a24dc46f8ccf84cd2020-11-24T21:30:49ZengCell Physiol Biochem Press GmbH & Co KGCellular Physiology and Biochemistry1015-89871421-97782016-06-0139135035910.1159/000445629445629Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic RatsDorota HarasiukMarcin BaranowskiPiotr ZabielskiAdrian ChabowskiJan GórskiBackground/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was reported recently. The aim of this study was to investigate effect of in vivo LXR activation on myocardial lipid metabolism under conditions of STZ-induced diabetes. Methods: Wistar rats were randomly divided into three experimental groups: non-diabetic control, treated with STZ, and treated with STZ and LXR agonist - TO901317. Diabetes was induced by a single intraperitonal injection of STZ at a dose of 55 mg/kg. LXR agonist was administrated once daily in the morning by an oral gavage at a dose of 10 mg/kg/d during the last week of the experiment. After anesthesia samples of blood and the left ventricle were taken. Results: TO901317 administration increased expression of both LXR isoforms and its target genes: sterol response element binding protein 1c (SREBP-1c) and acetyl-coenzyme A carboxylase 1 (ACC1) in the heart of streptozotocin-diabetic rats. Treatment with LXR agonist had no effect on plasma lipids and glucose in the diabetic rats. Concomitantly, content of the examined lipid classes in the diabetic heart (nonesterified fatty acids, triacylglycerols, phospholipids, cholesterol esters, ceramide) was unchanged after treatment with TO901317. On the contrary, myocardial level of cholesterol and diacylglycerols (DAG) was decreased after LXR activation in diabetic rats, the change in DAG level was associated with downregulated expression of adipose triglyceride lipase (ATGL). Conclusion: Activation of LXRs by TO901317 protects cardiomyocytes against DAG accumulation and thus may reverse disturbances in lipid metabolism observed in streptozotocin-diabetic heart.http://www.karger.com/Article/FullText/445629MyocardiumFatty acidsDAGCardiac muscleNuclear receptorsType 1 diabetes
collection DOAJ
language English
format Article
sources DOAJ
author Dorota Harasiuk
Marcin Baranowski
Piotr Zabielski
Adrian Chabowski
Jan Górski
spellingShingle Dorota Harasiuk
Marcin Baranowski
Piotr Zabielski
Adrian Chabowski
Jan Górski
Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
Cellular Physiology and Biochemistry
Myocardium
Fatty acids
DAG
Cardiac muscle
Nuclear receptors
Type 1 diabetes
author_facet Dorota Harasiuk
Marcin Baranowski
Piotr Zabielski
Adrian Chabowski
Jan Górski
author_sort Dorota Harasiuk
title Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
title_short Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
title_full Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
title_fullStr Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
title_full_unstemmed Liver X Receptor Agonist TO901317 Prevents Diacylglycerols Accumulation in the Heart of Streptozotocin-Diabetic Rats
title_sort liver x receptor agonist to901317 prevents diacylglycerols accumulation in the heart of streptozotocin-diabetic rats
publisher Cell Physiol Biochem Press GmbH & Co KG
series Cellular Physiology and Biochemistry
issn 1015-8987
1421-9778
publishDate 2016-06-01
description Background/Aims: Liver X receptors (LXRα and LXRβ) are ligand-activated transcription factors that regulate expression of genes involved in lipid and cholesterol metabolism. LXR expression has been identified in the heart, and enhanced LXR activity in the streptozotocin (STZ) diabetic myocardium was reported recently. The aim of this study was to investigate effect of in vivo LXR activation on myocardial lipid metabolism under conditions of STZ-induced diabetes. Methods: Wistar rats were randomly divided into three experimental groups: non-diabetic control, treated with STZ, and treated with STZ and LXR agonist - TO901317. Diabetes was induced by a single intraperitonal injection of STZ at a dose of 55 mg/kg. LXR agonist was administrated once daily in the morning by an oral gavage at a dose of 10 mg/kg/d during the last week of the experiment. After anesthesia samples of blood and the left ventricle were taken. Results: TO901317 administration increased expression of both LXR isoforms and its target genes: sterol response element binding protein 1c (SREBP-1c) and acetyl-coenzyme A carboxylase 1 (ACC1) in the heart of streptozotocin-diabetic rats. Treatment with LXR agonist had no effect on plasma lipids and glucose in the diabetic rats. Concomitantly, content of the examined lipid classes in the diabetic heart (nonesterified fatty acids, triacylglycerols, phospholipids, cholesterol esters, ceramide) was unchanged after treatment with TO901317. On the contrary, myocardial level of cholesterol and diacylglycerols (DAG) was decreased after LXR activation in diabetic rats, the change in DAG level was associated with downregulated expression of adipose triglyceride lipase (ATGL). Conclusion: Activation of LXRs by TO901317 protects cardiomyocytes against DAG accumulation and thus may reverse disturbances in lipid metabolism observed in streptozotocin-diabetic heart.
topic Myocardium
Fatty acids
DAG
Cardiac muscle
Nuclear receptors
Type 1 diabetes
url http://www.karger.com/Article/FullText/445629
work_keys_str_mv AT dorotaharasiuk liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats
AT marcinbaranowski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats
AT piotrzabielski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats
AT adrianchabowski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats
AT jangorski liverxreceptoragonistto901317preventsdiacylglycerolsaccumulationintheheartofstreptozotocindiabeticrats
_version_ 1725961540730880000